Approaches for Designing new Potent Inhibitors of Farnesyl Pyrophosphate Synthase

References

• Ogura K, Koyama T. Enzymatic aspects of isoprenoid chain elongation. Chem Rev. 1998;98:1263–1276.
   PubMed Web of Science ®Google Scholar
• Kellogg BA, Poulter CD. Chain elongation in the isoprenoid biosynthetic pathway. Curr Opin Chem Biol. 1997;1:570–578.
   PubMed Web of Science ®Google Scholar
• Eberl M, Hintz M, Reichenberg A, et al. Microbial isoprenoid biosynthesis and human γδ T cell activation. FEBS Lett. 2003;544:4–10.
   PubMed Web of Science ®Google Scholar
• Zhao L, Chang W-C, Xiao Y, et al. Methylerythritol phosphate pathway of isoprenoid biosynthesis. Annu Rev Biochem. 2013;82:497–530.
   PubMed Web of Science ®Google Scholar
• Reszka AA, Rodan GA. Nitrogen-containing bisphosphonate mechanism of action. Mini Rev Med Chem. 2004;4:711–719.
   PubMed Web of Science ®Google Scholar
• Miller K, Erez R, Segal E, et al. Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer–alendronate–taxane conjugate. Angew Chem Int Ed. 2009;48:2949–2954.
   PubMed Web of Science ®Google Scholar
• Clézardin P, Massaia M. Nitrogen-containing bisphosphonates and cancer immunotherapy. Curr Pharm Des. 2010;16:3007–3014.
   PubMed Web of Science ®Google Scholar
• Coleman RE. Risks and benefits of bisphosphonates. British J Cancer. 2008;98:1736–1740.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Cao R, Yin F, et al. Lipophilic bisphosphonates as dual farnesyl/geranylgeranyl diphosphate synthase inhibitors: an X-ray and NMR investigation. J Am Chem Soc. 2009;131:5153–5162.
   PubMed Web of Science ®Google Scholar
• Reddy R, Dietrich E, Lafontaine Y, et al. Bisphosphonated benzoxazinorifamycin prodrugs for the prevention and treatment of osteomyelitis. Chem Med Chem. 2008;3:1863–1868.
   Web of Science ®Google Scholar
• Sanders JM, Ghosh S, Chan JMW, et al. Quantitative structure−activity relationships for γδ T cell activation by bisphosphonates. J Med Chem. 2004;47:375–384.
   PubMed Web of Science ®Google Scholar
• Rodriguez JB, Szajnman SH. New antibacterials for the treatment of toxoplasmosis; a patent review. Expert Opinion Ther Patents. 2012;22:311–333.
   PubMed Web of Science ®Google Scholar
• Urbina JA, Moreno B, Vierkotter S, et al. Trypanosoma cruzi contains major pyrophosphate stores, and its growth in vitro and in vivo is blocked by pyrophosphate analogs. J Biol Chem. 1999;274:33609–33615.
   PubMed Web of Science ®Google Scholar
• Ghosh S, Chan JMW, Lea CR, et al. Effects of bisphosphonates on the growth of Entamoeba histolytica and plasmodium species in vitro and in vivo. J Med Chem. 2004;47:175–187.
   PubMed Web of Science ®Google Scholar
• Martin MB, Grimley JS, Lewis JC, et al. Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy. J Med Chem. 2001;44:909–916.
   PubMed Web of Science ®Google Scholar
• Martin MB, Sanders JM, Kendrick H, et al. Activity of bisphosphonates against Trypanosoma brucei rhodesiense. J Med Chem. 2002;45:2904–2914.
   PubMed Web of Science ®Google Scholar
• Yardley V, Khan AA, Martin MB, et al. In vivo activities of farnesyl pyrophosphate synthase inhibitors against Leishmania donovani and Toxoplasma gondii. Antimicrob Agents Chemother. 2002;46:929–931.
   PubMed Web of Science ®Google Scholar
• Blanchard L, Karst F. Characterization of a lysine-to-glutamic acid mutation in a conservative sequence of farnesyl diphosphate synthase from Saccharomyces cerevisiae. Gene. 1993;125:185–189.
   PubMed Web of Science ®Google Scholar
• Song L, Poulter CD. Yeast farnesyl-diphosphate synthase: site-directed mutagenesis of residues in highly conserved prenyltransferase domains I and II. Proc Natl Acad Sci USA. 1994;91:3044–3048.
   PubMed Web of Science ®Google Scholar
• Sun S, McKenna CE. Farnesyl pyrophosphate synthase modulators: a patent review (2006 - 2010). Expert Opinion Ther Patents. 2011;21:1433–1451.
   PubMed Web of Science ®Google Scholar
• Clarke S. Protein isoprenylation and methylation at carboxyl-terminal cysteine residues. Annu Rev Biochem. 1992;61:355–386.
   PubMed Web of Science ®Google Scholar
• Luckman SP, Hughes DE, Coxon FP, et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res. 1998;13:581–589.
   PubMed Web of Science ®Google Scholar
• Zhang FL, Casey PJ. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem. 1996;65:241–269.
   PubMed Web of Science ®Google Scholar
• Kitten GT, Nigg EA. The CAAX motif is required for isoprenylation, carboxyl methylation, and nuclear membrane association of lamin B2. J Cell Biol. 1991;113:13–23.
   PubMed Web of Science ®Google Scholar
• Hancock JF, Magee AI, Childs JE, et al. All Ras proteins are polyisoprenylated but only some are palmitoylated. Cell. 1989;57:1167–1177.
   PubMed Web of Science ®Google Scholar
• Eastman RT, White J, Hucke O, et al. Resistance to a protein farnesyltransferase inhibitor in Plasmodium falciparum. J Biol Chem. 2005;280:13554–13559.
   PubMed Web of Science ®Google Scholar
• Yokoyama K, Trobridge P, Buckner FS, et al. The effects of protein farnesyltransferase inhibitors on trypanosomatids: inhibition of protein farnesylation and cell growth. Mol Biochem Parasitol. 1998;94:87–97.
   PubMed Web of Science ®Google Scholar
• Yokoyama K, Trobridge P, Buckner FS, et al. Protein Farnesyltransferase from Trypanosoma brucei: A HETERODIMER OF 61- AND 65-kDa SUBUNITS AS A NEW TARGET FOR ANTIPARASITE THERAPEUTICS. J Biol Chem. 1998;273:26497–26505.
   PubMed Web of Science ®Google Scholar
• Cuevas IC, Rohloff P, Sanchez DO, et al. Characterization of farnesylated protein tyrosine phosphatase TcPRL-1 from Trypanosoma cruzi. Eukaryot Cell. 2005;4:1550–1561.
   PubMed Web of Science ®Google Scholar
• Lynen F, Agranoff BW, Eggerer H, et al. γ,γ-Dimethyl-allyl-pyrophosphat und Geranyl-pyrophosphat, biologische Vorstufen des Squalens Zur Biosynthese der Terpene, VI1). Angew Chem. 1959;71:657–663.
   Web of Science ®Google Scholar
• Roelofs AJ, Thompson K, Ebetino FH, et al. Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages. Curr Pharm Des. 2010;16:2950–2960.
   PubMed Web of Science ®Google Scholar
• Fleisch H, Russell RGG, Straumann F. Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature. 1966;212:901–903.
   PubMed Web of Science ®Google Scholar
• Francis MD, Graham RGG, Russell G, et al. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science. 1969;165:1264–1266.
   PubMed Web of Science ®Google Scholar
• Fleisch H, Graham RGG, Russell G, et al. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science. 1969;165:1262–1264.
   PubMed Web of Science ®Google Scholar
• Russell RGG. Bisphosphonates: the first 40 years. Bone. 2011;49:2–19.
   PubMed Web of Science ®Google Scholar
• Reszka AA, Rodan GA. Mechanism of action of bisphosphonates. Curr Osteoporos Rep. 2003;1:45–52.
   PubMedGoogle Scholar
• Russell RGG, Rogers, MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone. 1999;25:97–106.
   PubMed Web of Science ®Google Scholar
• Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008;83:1032–1045.
   PubMed Web of Science ®Google Scholar
• Plotkin LI, Weinstein RS, Parfitt AM, et al. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest. 1999;104:1363–1374.
   PubMed Web of Science ®Google Scholar
• Plotkin LI, Aguirre JI, Kousteni S, et al. Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. J Biol Chem. 2005;280:7317–7325.
   PubMed Web of Science ®Google Scholar
• Gumienna-Kontecka E, Silvagni R, Lipinski R, et al. Bisphosphonate chelating agents: complexation of Fe(III) and Al(III) by 1-phenyl-1-hydroxymethylene bisphosphonate and its analogues. Inorg Chimica Acta. 2002;339:111–118.
   Web of Science ®Google Scholar
• Crisponi G, Nurchi VM, Pivetta T, et al. Towards a new attenuating compound: A potentiometric, spectrophotometric and NMR equilibrium study on Fe(III), Al(III) and a new tetradentate mixed bisphosphonate–hydroxypyridinonate ligand. J Inorg Biochem. 2008;102:1486–1494.
   PubMed Web of Science ®Google Scholar
• Gumienna-Kontecka E, Jezierska J, Lecouvey M, et al. Bisphosphonate chelating agents. Coordination ability of 1-phenyl-1-hydroxymethylene bisphosphonate towards Cu2+ ions. J Inorg Biochem. 2002;89:13–17.
   PubMed Web of Science ®Google Scholar
• Dolbecq A, Mialane P, Sécheresse F, et al. Functionalized polyoxometalates with covalently linked bisphosphonate, N-donor or carboxylate ligands: from electrocatalytic to optical properties. Chem Commun. 2012;48:8299–8316.
   PubMed Web of Science ®Google Scholar
• Ebetino FH, Francis MD, Rogers MJ, et al. Mechanisms of action of etidronate and other bisphosphonates. Rev Contemp Pharmacother. 1998;9:233–243.
   Web of Science ®Google Scholar
• Matczak-Jon E, Kurzak B, Kamecka A, et al. Interactions of zinc(II), magnesium(II) and calcium(II) with aminomethane-1,1-diphosphonic acids in aqueous solutions. Polyhedron. 2002;21:321–332.
   Web of Science ®Google Scholar
• Van Beek E, Löwik C, Que I, et al. Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl with an amino group. J Bone Miner Res. 1996;11:1492–1497.
   PubMed Web of Science ®Google Scholar
• Marma MS, Xia Z, Stewart C, et al. Synthesis and biological evaluation of α-halogenated bisphosphonate and phosphonocarboxylate analogues of risedronate. J Med Chem. 2007;50:5967–5975.
   PubMed Web of Science ®Google Scholar
• McKenna CE, Shen P-D. Fluorination of methanediphosphonate esters by perchloryl fluoride. Synthesis of fluoromethanediphosphonic acid and difluoromethanediphosphonic acid. J Org Chem. 1981;46:4573–4576.
   Web of Science ®Google Scholar
• Romanenko VD, Kukhar VP. Fluorinated phosphonates: synthesis and biomedical application. Chem Rev. 2006;106:3868–3935.
   PubMed Web of Science ®Google Scholar
• Berkowitz DB, Bose M. (α-Monofluoroalkyl)phosphonates: a class of isoacidic and “tunable” mimics of biological phosphates. J Fluorine Chem. 2001;112:13–33.
   Web of Science ®Google Scholar
• Blackburn GM, England DA, Kolkmann F. Monofluoro- and difluoro-methylenebisphosphonic acids: isopolar analogues of pyrophosphoric acid. Chem Commun. 1981;1981:930–932.
   Web of Science ®Google Scholar
• Dhar MK, Koul A, Kaul S. Farnesyl pyrophosphate synthase: a key enzyme in isoprenoid biosynthetic pathway and potential molecular target for drug development. New Biotechnology. 2013;30:115–123.
   Web of Science ®Google Scholar
• Ebetino FH, Hogan A–ML, Sun S, et al. The relationship between the chemistry and biological activity of the bisphosphonates. Bone. 2011;49:20–33.
   PubMed Web of Science ®Google Scholar
• Ohno K, Mori K, Orita M, et al. Computational insights into binding of bisphosphates to farnesyl pyrophosphate synthase. Curr Med Chem. 2011;18:220–233.
   PubMed Web of Science ®Google Scholar
• Cornforth JW, Cornforth RH, Popják G, et al. Studies on the biosynthesis of cholesterol. XX. Steric course of decarboxylation of 5-pyrophosphomevalonate and of the carbon to carbon bond formation in the biosynthesis of farnesyl pyrophosphate. J Biol Chem. 1966;241:3970–3987.
   PubMed Web of Science ®Google Scholar
• Kloer DP, Welsch R, Beyer P, et al. Structure and reaction geometry of geranylgeranyl diphosphate synthase from Sinapis alba. Biochemistry. 2006;45:15197–15204.
   PubMed Web of Science ®Google Scholar
• Gabelli SB, McLellan JS, Montalvetti A, et al. Structure and mechanism of the farnesyl diphosphate synthase from Trypanosoma cruzi: implications for drug design. Proteins. 2006;62:80–88.
   PubMed Web of Science ®Google Scholar
• Martin MB, Arnold W, Heath HT, et al. Nitrogen-containing bisphosphonates as carbocation transition state analogs for isoprenoid biosynthesis. Biochem Biophys Res Commun. 1999;263:754–758.
   PubMed Web of Science ®Google Scholar
• Kavanagh KL, Guo K, Dunford JE, et al. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci USA. 2006;103:7829–7834.
   PubMed Web of Science ®Google Scholar
• Rondeau J−M, Bitsch F, Bourgier E, et al. Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs. ChemMedChem. 2006;1:267−73.
   PubMed Web of Science ®Google Scholar
• De Schutter JW, Park J, Leung CY, et al. Multistage screening reveals chameleon ligands of the human farnesyl pyrophosphate synthase: implications to drug discovery for neurodegenerative diseases. J Med Chem. 2014;57:5764–5776.
   PubMed Web of Science ®Google Scholar
• Park J, Lin Y-S, De Schutter JW, et al. Ternary complex structures of human farnesyl pyrophosphate synthase bound with a novel inhibitor and secondary ligands provide insights into the molecular details of the enzyme’s active site closure. BMC Struct Biol. 2012;12:32.
   PubMed Web of Science ®Google Scholar
• Park J, Lin Y-S, Tsantrizos YS, et al. Structure of human farnesyl pyrophosphate synthase in complex with an aminopyridine bisphosphonate and two molecules of inorganic phosphate. Acta Crystallogr Sect F Struct Biol Commun. 2014;70:299–304.
   PubMed Web of Science ®Google Scholar
• Leung CY, Park J, De Schutter JW, et al. Thienopyrimidine bisphosphonate (ThPBP) inhibitors of the human farnesyl pyrophosphate synthase: optimization and characterization of the mode of inhibition. J Med Chem. 2013;56:7939–7950.
   PubMed Web of Science ®Google Scholar
• Lin Y-S, Park J, De Schutter JW, et al. Design and synthesis of active site inhibitors of the human farnesyl pyrophosphate synthase: apoptosis and inhibition of ERK phosphorylation in multiple myeloma cells. J Med Chem. 2012;55:3201–3215.
   PubMed Web of Science ®Google Scholar
• Tarshis LC, Yan M, Poulter CD, et al. Crystal structure of recombinant farnesyl diphosphate synthase at 2.6-Å resolution. Biochemistry. 1994;33:10871–10877.
   PubMed Web of Science ®Google Scholar
• Tarshis LC, Proteau PJ, Kellogg BA, et al. Regulation of product chain length by isoprenyl diphosphate synthases. Proc Natl Acad Sci USA. 1996;93:15018–15023.
   PubMed Web of Science ®Google Scholar
• Guo R-T, Cao R, Liang P-H, et al. Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases. Proc Natl Acad Sci USA. 2007;104:10022–10027.
   PubMed Web of Science ®Google Scholar
• Huang C-H, Gabelli SB, Oldfield E, et al. Binding of nitrogen-containing bisphosphonates (N-BPs) to the Trypanosoma cruzi farnesyl diphosphate synthase homodimer. Proteins. 2010;78:888–899.
   PubMed Web of Science ®Google Scholar
• Aripirala S, Szajnman SH, Jakoncic J, et al. Design, synthesis, calorimetry, and crystallographic analysis of 2-alkylaminoethyl-1,1-bisphosphonates as inhibitors of Trypanosoma cruzi farnesyl diphosphate synthase. J Med Chem. 2012;55:6445–6454.
   PubMed Web of Science ®Google Scholar
• Cao R, Chen CKM, Guo R-T, et al. Structures of a potent phenylalkyl bisphosphonate inhibitor bound to farnesyl and geranylgeranyl diphosphate synthases. Proteins. 2008;73:431–439.
   PubMed Web of Science ®Google Scholar
• Mao J, Gao Y-G, Odeh S, et al. Crystallization and preliminary X-ray diffraction study of the farnesyl diphosphate synthase from Trypanosoma brucei. Acta Crystallogr D Biol Crystallogr. 2004;60:1863–1866.
   PubMed Web of Science ®Google Scholar
• Aripirala S, Gonzalez-Pacanowska D, Oldfield E, et al. Structural and thermodynamic basis of the inhibition of Leishmania major farnesyl diphosphate synthase by nitrogen-containing bisphosphonates. Acta Crystallogr Sect D Biol Crystallogr. 2014;70:802–810.
   PubMed Web of Science ®Google Scholar
• Artz JD, Wernimont AK, Dunford JE, et al. Molecular characterization of a novel geranylgeranyl pyrophosphate synthase from plasmodium parasites. J Biol Chem. 2011;286:3315–3322.
   PubMed Web of Science ®Google Scholar
• Wang W, Dong C, McNeil M, et al. The structural basis of chain length control in Rv1086. J Mol Biol. 2008;381:129–140.
   PubMed Web of Science ®Google Scholar
• Hosfield DJ, Zhang Y, Dougan DR, et al. Structural basis for bisphosphonate-mediated inhibition of isoprenoid biosynthesis. J Biol Chem. 2003;278:18401–18407.
   PubMed Web of Science ®Google Scholar
• Roberts E, Eargle J, Wright D, et al. MultiSeq: unifying sequence and structure data for evolutionary analysis. BMC Bioinformatics. 2006;7:382.
   PubMed Web of Science ®Google Scholar
• Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Molec Graphics. 1996;14:33–38.
   PubMed Web of Science ®Google Scholar
• King HL Jr., Rilling HC. Avian liver prenyltransferase. The role of metal in substrate binding and the orientation of substrates during catalysis. Biochemistry. 1977;16:3815–3819.
   PubMed Web of Science ®Google Scholar
• Liu Y-L, Cao R, Wang Y, et al. Farnesyl diphosphate synthase inhibitors with unique ligand-binding geometries. ACS Med Chem Lett. 2015;6:349–354.
   PubMed Web of Science ®Google Scholar
• Ling Y, Li Z-H, Miranda K, et al. The farnesyldiphosphate/geranylgeranyl-diphosphate synthase of Toxoplasma gondii is a bifunctional enzyme and a molecular target of bisphosphonates. J Biol Chem. 2007;282:30804–30816.
   PubMed Web of Science ®Google Scholar
• Biasini M, Bienert S, Waterhouse A, et al. SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information. Nucleic Acids Res. 2014;42:W252–8.
   PubMed Web of Science ®Google Scholar
• Arnold K, Bordoli L, Kopp J, et al. The SWISS-MODEL Workspace: A web-based environment for protein structure homology modelling. Bioinformatics. 2006;22:195–201.
   PubMed Web of Science ®Google Scholar
• Kiefer F, Arnold K, Künzli M, et al. The SWISS-MODEL Repository and associated resources. Nucleic Acids Res. 2009;37:D387–92.
   PubMed Web of Science ®Google Scholar
• Chan H-C, Feng X, Ko T-P, et al. Structure and inhibition of tuberculosinol synthase and decaprenyl diphosphate synthase from Mycobacterium tuberculosis. J Am Chem Soc. 2014;136:2892–2896.
   PubMed Web of Science ®Google Scholar
• Rosso VS, Szajnman SH, Malayil L, et al. Synthesis and biological evaluation of new 2-alkylaminoethyl-1,1-bisphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii targeting farnesyl diphosphate synthase. Bioorg Med Chem. 2011;19:2211–2217.
   PubMed Web of Science ®Google Scholar
• Szajnman SH, Garcı´a Liñares GE, Li Z-H, et al. Synthesis and biological evaluation of 2-alkylaminoethyl-1,1-bisphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii targeting farnesyl diphosphate synthase. Bioorg Med Chem. 2008;16:3283–3290.
   PubMed Web of Science ®Google Scholar
• Ohnuma S, et al. Conversion from farnesyl diphosphate synthase to geranylgeranyl diphosphate synthase by random chemical mutagenesis. J Biol Chem. 1996;271:10087−95.
   PubMed Web of Science ®Google Scholar
• Yokoyama T, Mizuguchi M, Ostermann A, et al. Protonation state and hydration of bisphosphonate bound to farnesyl pyrophosphate synthase. J Med Chem. 2015;58:7549–7556.
   PubMed Web of Science ®Google Scholar
• Ferrer-Casal M, Li C, Galizzi M, et al. New insights into molecular recognition of 1,1-bisphosphonic acids by farnesyl diphosphate synthase. Bioorg Med Chem. 2014;22:398–405.
   PubMed Web of Science ®Google Scholar
• Demoro B, Caruso F, Rossi M, et al. Risedronate metal complexes potentially active against Chagas disease. J Inorg Biochem. 2010;104:1252–1258.
   PubMed Web of Science ®Google Scholar
• Szajnman SH, Montalvetti A, Wang Y, et al. Bisphosphonates derived from fatty acids are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase. Bioorg Med Chem Lett. 2003;13:3231–3235.
   PubMed Web of Science ®Google Scholar
• Szajnman SH, Rosso VS, Malayil L, et al. Design, synthesis and biological evaluation of 1-(fluoroalkylidene)-1,1-bisphosphonic acids against Toxoplasma gondii targeting farnesyl diphosphate synthase. Org Biomol Chem. 2012;10:1424–1433.
   PubMed Web of Science ®Google Scholar
• Recher M, Barboza AP, Li Z-H, et al. Design, synthesis and biological evaluation of sulfur-containing 1,1-bisphosphonic acids as antiparasitic agents. Eur J Med Chem. 2013;60:431–440.
   PubMed Web of Science ®Google Scholar
• Silverman RB. In the organic chemistry of drug design and drug action. San Diego: Academic Press; 1999. p. 171–172.
   Google Scholar
• Rich DH. Pepstatin-derived inhibitors of aspartic proteinases. A close look at an apparent transition-state analog inhibitor. J Med Chem. 1985;28:263–273.
   PubMed Web of Science ®Google Scholar
• Bergstrom JD, Bostedor RG, Masarachia PJ, et al. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys. 2000;373:231–241.
   PubMed Web of Science ®Google Scholar
• Dunford JE, Kwaasi AA, Rogers MJ, et al. Structure–activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase. J Med Chem. 2008;51:2187–2195.
   PubMed Web of Science ®Google Scholar
• Ebetino FH, Dunford JE, Lundy MW, et al. A mirror image pair of bisphosphonate analogs further demonstrates the mode of binding of the bisphosphonates in farnexyl pyrophosphate synthase. Bone. 2008;42(Supp 1):S36–7.
   Google Scholar
• Tsoumpra MK, Muniz JR, Barnett BL, et al. The inhibition of human farnesyl pyrophosphate synthase by nitrogen-containing bisphosphonates. Elucidating the role of active site threonine 201 and tyrosine 204 residues using enzyme mutants. Bone. 2015;81:478–486.
   PubMed Web of Science ®Google Scholar
• Cotesta S, Jahnke W, Rondeau JM, et al. Phenylalkyl-imidazole-bisphosphonate compounds. WO2010076258A1. 2010.
   Google Scholar
• Gao J, Liu J, Qiu Y, et al. Multi-target-directed design, syntheses, and characterization of fluorescent bisphosphonate derivatives as multifunctional enzyme inhibitors in mevalonate pathway. Biochim Biophys Acta. 2013;1830:3635–3642.
   PubMed Web of Science ®Google Scholar
• Gao J, Chu X, Qiu Y, et al. Discovery of potent inhibitor for farnesyl pyrophosphate synthase in the mevalonate pathway. Chem Commun. 2010;46:5340–5342.
   PubMed Web of Science ®Google Scholar
• Kieczykowski GR, Jobson RB, Melillo DG, et al. Preparation of (4-amino-1-hydroxybutylidene) bisphosphonic acid sodium salt, MK-217 (alendronate sodium). An improved procedure for the preparation of 1-hydroxy-1,1-bisphosphonic acids. J Org Chem. 1995;60:8310–8312.
   Web of Science ®Google Scholar
• Bhattacharya AK, Thyagarajan G. The Michaelis–Arbuzov rearrangement. Chem Rev. 1981;81:415–430.
   Web of Science ®Google Scholar
• Pudovik AN, Konovalova IV. Addition reactions of esters of phosphorus(III) acids with unsaturated systems. Synthesis. 1979;1979:81–96.
   Google Scholar
• Lazzarato L, Rolando B, Lolli ML, et al. Synthesis of NO-donor bisphosphonates and their in-vitro action on bone resorption. J Med Chem. 2005;48:1322–1329.
   PubMed Web of Science ®Google Scholar
• Vachal P, Hale JJ, Lu Z, et al. Synthesis and study of alendronate derivatives as potential prodrugs of alendronate sodium for the treatment of low bone density and osteoporosis. J Med Chem. 2006;49:3060–3063.
   PubMed Web of Science ®Google Scholar
• Kolodyazhnaya AO, Kolodyazhnaya OO, Kolodyazhnyi OI. An efficient method for the phosphonation of C=X compounds. Russian J General Chem. 2010;80:709–722.
   Web of Science ®Google Scholar
• Rodriguez JB. Tetraethyl Vinylidenebisphosphonate: a versatile synthon for the preparation of bisphosphonates. Synthesis. 2014;46:1129–1142.
   Web of Science ®Google Scholar
• Degenhardt CR, Burdsall DC. Synthesis of ethenylidenebis(phosphonic acid) and its tetraalkyl esters. J Org Chem. 1986;51:3488–3490.
   Web of Science ®Google Scholar
• Lolli ML, Lazzarato L, Di Stilo A, et al. Michael addition of Grignard reagents to tetraethyl ethenylidenebisphosphonate. J Organomet Chem. 2002;650:77–83.
   Web of Science ®Google Scholar
• Wasielewski C, Antczak K. Aminophosphonic acids; XVI1. A new and facile synthesis of phosphinothricine and 2-amino-4-phosphonobutanoic acid. Synthesis. 1981;1981:540–541.
   Google Scholar
• Kurzak B, Goldeman W, Szpak M, et al. Synthesis of N-methyl alkylaminomethane-1,1-diphosphonic acids and evaluation of their complex-formation abilities towards copper(II). Polyhedron. 2015;85:675–684.
   Web of Science ®Google Scholar
• Liu J, Liu W, Ge H, et al. Syntheses and characterization of non-bisphosphonate quinoline derivatives as new FPPS inhibitors. Biochim Biophys Acta. 2014;1840:1051–1062.
   PubMed Web of Science ®Google Scholar
• Lindert S, Zhu W, Liu Y-L, et al. Farnesyl diphosphate synthase inhibitors from in silico screening. Chem Biol Drug Des. 2013;81:742–748.
   PubMed Web of Science ®Google Scholar
• Jahnke W, Rondeau J-M, Cotesta S, et al. Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery. Nat Chem Biol. 2010;6:660–666.
   PubMed Web of Science ®Google Scholar
• Marzinzik AL, Amstutz R, Bold G, et al. Discovery of novel allosteric non-bisphosphonate inhibitors of farnesyl pyrophosphate synthase by integrated lead finding. ChemMedChem. 2015;10:1884–1891.
   PubMed Web of Science ®Google Scholar
• Jahnke W, Bold G, Marzinzik AL, et al. A general strategy for targeting drugs to bone. Angew Chem Int Ed. 2015;54:14575–14579.
   PubMed Web of Science ®Google Scholar